{"success":true,"data":{"pressRelease":{"id":"33240","rtpr_id":"nBw5sDb6Sa","ticker":"ZURA","exchange":"NASDAQ","all_tickers":["ZURA"],"title":"Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer","author":"Business Wire","published_at":"2026-05-13T11:30:00.232Z","article_body":"Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief\nBusiness Officer\n\nZura Bio Limited\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fzurabio.com%2F&esheet=54534943&newsitemid=20260513568466&lan=en-US&anchor=Zura+Bio+Limited&index=1&md5=233d487cf4c29d931c24f3c95175bb35)\n(Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing\nnovel and differentiated medicines to meaningfully improve the lives of\npatients with serious and debilitating autoimmune and inflammatory diseases,\ntoday announced the appointment of Muzammil Mustufa as Chief Business Officer\n(CBO). Mr. Mustufa will oversee corporate strategy, business development,\ncommercial planning, and investor relations efforts.\n\nMr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology\nexperience to Zura, with extensive experience in immunology, rare disease, and\nother therapeutic areas. Most recently, he served as Vice President of\nCorporate Strategy at Amicus Therapeutics, where he played an integral part in\nthe global launch and commercialization strategies of two innovative medicines\nin orphan diseases. He subsequently led integration planning for Amicus in\nconnection with BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of the\ncompany. Earlier in his career, Mr. Mustufa held roles at GSK plc, The Frankel\nGroup, and The D.E. Shaw Group.\n\n\"We are thrilled to welcome Muz to Zura as we approach key clinical and\ncorporate milestones for tibulizumab,” said Sandeep Kulkarni, M.D.,\nco-founder and Chief Executive Officer of Zura Bio. “He brings a rare\ncombination of commercial, strategic, and financial acumen that will elevate\nand complement our leadership team’s capabilities. Muz is the perfect fit\nfor the company as we continue to explore tibulizumab’s potential to\nredefine treatment across multiple autoimmune indications as well as pursue\nopportunities to further advance our mission.”\n\n\"I am excited to be joining Zura and to contribute during what is clearly a\ndefining period for the company,” said Mr. Mustufa. “The science behind\ntibulizumab — a first- and only-in-class bispecific simultaneously blocking\nthe IL-17 and BAFF pathways — reflects an approach that has the potential to\nimprove outcomes for patients with serious and complex immune system\ndisorders. I look forward to partnering with Sandeep, our talented team, and\nthe Board of Directors as we prepare for our readouts and the company’s next\nphase of growth.\"\n\nABOUT ZURA\n\nZura is a clinical-stage, multi-asset immunology company developing novel\ndual-pathway antibodies for autoimmune and inflammatory diseases with unmet\nneed. Zura’s pipeline includes product candidates designed to target key\nmechanisms of immune system imbalance, with the goal of improving efficacy,\nsafety, and dosing convenience for patients.\n\nZura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in\ntwo Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis\nsuppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc).\nAdditional product candidates torudokimab (ZB-880) and crebankitug (ZB-168)\nhave completed Phase 1/1b studies and are being evaluated for their potential\nacross a range of autoimmune and inflammatory conditions.\n\nFor more information, please visit www.zurabio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zurabio.com&esheet=54534943&newsitemid=20260513568466&lan=en-US&anchor=www.zurabio.com&index=2&md5=65187373aa3c228cc342f71cd17ce2b3)\n.\n\nFORWARD-LOOKING STATEMENTS\n\nAny statements contained in this press release that do not describe historical\nfacts may constitute “forward‑looking statements” as that term is\ndefined in the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified by words and phrases such as “anticipate,”\n“believe,” “continue,” “could,” “designed to,” “expect,”\n“goal,” “intend,” “may,” “outlook,” “plan,”\n“potential,” “should,” “will,” and similar expressions, and are\nbased on Zura’s current beliefs and expectations. These forward‑looking\nstatements include, but are not limited to, statements regarding the\ndevelopment and potential therapeutic benefits of Zura’s product candidates;\nthe timing, progress, design and results of Zura’s current and future\nclinical trials, including the anticipated reporting of data therefrom; the\npotential to expand Zura’s product candidates into additional indications;\nthe sufficiency of Zura’s cash resources and projected cash runway; and\nother statements that are not historical facts. These statements involve risks\nand uncertainties that could cause actual results to differ materially from\nthose reflected in such forward‑looking statements. Risks and uncertainties\nthat may cause actual results to differ materially include, but are not\nlimited to: uncertainties inherent in the development of therapeutic product\ncandidates, such as the risk that one or more of Zura’s current or future\nproduct candidates may not be successfully developed or commercialized; the\nrisk of delay or cessation of any planned clinical trials of Zura’s current\nor future product candidates; the risk that prior results, including signals\nof safety, activity or durability of effect observed in preclinical studies or\nearlier clinical trials, may not be replicated or may not continue in ongoing\nor future studies or clinical trials; the risk that modeling data indicating\ntherapeutic potential, or clinical evidence from other drug candidates, may\nnot be predictive of results in Zura’s current or future clinical trials;\nthe risk that Zura’s product candidates or procedures in connection with\ntheir administration may not have the safety or efficacy profiles anticipated;\nrisks related to the accuracy of Zura’s estimates of expenses, capital\nrequirements and needs for additional financing; changes in expected or\nexisting competition; changes in the regulatory environment; uncertainties\nrelated to the timing and outcome of the regulatory approval process;\nunexpected litigation or other disputes; the impact of macroeconomic\nconditions on Zura’s business, clinical trials and financial position; and\nother risks and uncertainties to be described in Zura’s Annual Report on\nForm 10‑K for the year ended December 31, 2025, and other filings with the\nSecurities and Exchange Commission. Any forward‑looking statements speak\nonly as of the date of this press release and are based on information\navailable to Zura as of the date hereof. Zura assumes no obligation to, and\ndoes not intend to, update any forward‑looking statements, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260513568466/en/\n(https://www.businesswire.com/news/home/20260513568466/en/)\n\nInvestor and media inquiries:\n\nir@zurabio.com (mailto:ir@zurabio.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5sDb6Sa","title":"Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer","author":"Business Wire","ticker":"ZURA","created":"2026-05-13T11:30:00.232Z","tickers":["ZURA"],"exchange":"NASDAQ","article_body":"Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief\nBusiness Officer\n\nZura Bio Limited\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fzurabio.com%2F&esheet=54534943&newsitemid=20260513568466&lan=en-US&anchor=Zura+Bio+Limited&index=1&md5=233d487cf4c29d931c24f3c95175bb35)\n(Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing\nnovel and differentiated medicines to meaningfully improve the lives of\npatients with serious and debilitating autoimmune and inflammatory diseases,\ntoday announced the appointment of Muzammil Mustufa as Chief Business Officer\n(CBO). Mr. Mustufa will oversee corporate strategy, business development,\ncommercial planning, and investor relations efforts.\n\nMr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology\nexperience to Zura, with extensive experience in immunology, rare disease, and\nother therapeutic areas. Most recently, he served as Vice President of\nCorporate Strategy at Amicus Therapeutics, where he played an integral part in\nthe global launch and commercialization strategies of two innovative medicines\nin orphan diseases. He subsequently led integration planning for Amicus in\nconnection with BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of the\ncompany. Earlier in his career, Mr. Mustufa held roles at GSK plc, The Frankel\nGroup, and The D.E. Shaw Group.\n\n\"We are thrilled to welcome Muz to Zura as we approach key clinical and\ncorporate milestones for tibulizumab,” said Sandeep Kulkarni, M.D.,\nco-founder and Chief Executive Officer of Zura Bio. “He brings a rare\ncombination of commercial, strategic, and financial acumen that will elevate\nand complement our leadership team’s capabilities. Muz is the perfect fit\nfor the company as we continue to explore tibulizumab’s potential to\nredefine treatment across multiple autoimmune indications as well as pursue\nopportunities to further advance our mission.”\n\n\"I am excited to be joining Zura and to contribute during what is clearly a\ndefining period for the company,” said Mr. Mustufa. “The science behind\ntibulizumab — a first- and only-in-class bispecific simultaneously blocking\nthe IL-17 and BAFF pathways — reflects an approach that has the potential to\nimprove outcomes for patients with serious and complex immune system\ndisorders. I look forward to partnering with Sandeep, our talented team, and\nthe Board of Directors as we prepare for our readouts and the company’s next\nphase of growth.\"\n\nABOUT ZURA\n\nZura is a clinical-stage, multi-asset immunology company developing novel\ndual-pathway antibodies for autoimmune and inflammatory diseases with unmet\nneed. Zura’s pipeline includes product candidates designed to target key\nmechanisms of immune system imbalance, with the goal of improving efficacy,\nsafety, and dosing convenience for patients.\n\nZura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in\ntwo Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis\nsuppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc).\nAdditional product candidates torudokimab (ZB-880) and crebankitug (ZB-168)\nhave completed Phase 1/1b studies and are being evaluated for their potential\nacross a range of autoimmune and inflammatory conditions.\n\nFor more information, please visit www.zurabio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.zurabio.com&esheet=54534943&newsitemid=20260513568466&lan=en-US&anchor=www.zurabio.com&index=2&md5=65187373aa3c228cc342f71cd17ce2b3)\n.\n\nFORWARD-LOOKING STATEMENTS\n\nAny statements contained in this press release that do not describe historical\nfacts may constitute “forward‑looking statements” as that term is\ndefined in the Private Securities Litigation Reform Act of 1995. These\nstatements may be identified by words and phrases such as “anticipate,”\n“believe,” “continue,” “could,” “designed to,” “expect,”\n“goal,” “intend,” “may,” “outlook,” “plan,”\n“potential,” “should,” “will,” and similar expressions, and are\nbased on Zura’s current beliefs and expectations. These forward‑looking\nstatements include, but are not limited to, statements regarding the\ndevelopment and potential therapeutic benefits of Zura’s product candidates;\nthe timing, progress, design and results of Zura’s current and future\nclinical trials, including the anticipated reporting of data therefrom; the\npotential to expand Zura’s product candidates into additional indications;\nthe sufficiency of Zura’s cash resources and projected cash runway; and\nother statements that are not historical facts. These statements involve risks\nand uncertainties that could cause actual results to differ materially from\nthose reflected in such forward‑looking statements. Risks and uncertainties\nthat may cause actual results to differ materially include, but are not\nlimited to: uncertainties inherent in the development of therapeutic product\ncandidates, such as the risk that one or more of Zura’s current or future\nproduct candidates may not be successfully developed or commercialized; the\nrisk of delay or cessation of any planned clinical trials of Zura’s current\nor future product candidates; the risk that prior results, including signals\nof safety, activity or durability of effect observed in preclinical studies or\nearlier clinical trials, may not be replicated or may not continue in ongoing\nor future studies or clinical trials; the risk that modeling data indicating\ntherapeutic potential, or clinical evidence from other drug candidates, may\nnot be predictive of results in Zura’s current or future clinical trials;\nthe risk that Zura’s product candidates or procedures in connection with\ntheir administration may not have the safety or efficacy profiles anticipated;\nrisks related to the accuracy of Zura’s estimates of expenses, capital\nrequirements and needs for additional financing; changes in expected or\nexisting competition; changes in the regulatory environment; uncertainties\nrelated to the timing and outcome of the regulatory approval process;\nunexpected litigation or other disputes; the impact of macroeconomic\nconditions on Zura’s business, clinical trials and financial position; and\nother risks and uncertainties to be described in Zura’s Annual Report on\nForm 10‑K for the year ended December 31, 2025, and other filings with the\nSecurities and Exchange Commission. Any forward‑looking statements speak\nonly as of the date of this press release and are based on information\navailable to Zura as of the date hereof. Zura assumes no obligation to, and\ndoes not intend to, update any forward‑looking statements, whether as a\nresult of new information, future events or otherwise, except as required by\nlaw.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260513568466/en/\n(https://www.businesswire.com/news/home/20260513568466/en/)\n\nInvestor and media inquiries:\n\nir@zurabio.com (mailto:ir@zurabio.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-13T11:30:00.293036931Z","server_sent_at_ms":1778671800293},"received_at":"2026-05-13T11:30:00.489Z","source_url":"https://www.businesswire.com/news/home/20260513568466/en/"},"analysis":null,"durationMs":null,"modelName":null}}